Analysis of the blood of advanced prostate cancer patients helps to select the optimal therapy
Blood test helps to decide which prostate cancer therapy to choose - health science news

A new blood test has been developed that will help oncologists to decide whether a hormonal or a chemotherapy should be followed for the treatment of advanced prostate cancer. The test is based on the presence or absence of a nuclear protein in cancer cells that have left the prostate. If this protein (AR-V7) is absent, the best treatment option is to continue with a hormone-based therapy with androgen-receptor signaling inhibitors. They make use of the dependency of the cancer on testosterone. If AR-V7 (a splice variant of the androgen receptor) is present, the cancer has found a way to grow independently of testosterone, so that hormone therapy will be without effect, and chemotherapy should be chosen.

Read the full story: Lawson Health Research Institute
Scientific publication: JAMA Oncology